Compare Citius Pharmaceuticals Inc (CTXR) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Mondaycom Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Mondaycom Ltd trades at $88.43 (market cap $3.76B). The key difference: Mondaycom Ltd is far larger — about 276.1× Citius Pharmaceuticals Inc's market cap, and Mondaycom Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Mondaycom Ltd for 16 Days on average.
| CTXR | MNDY | |
|---|---|---|
Market Cap | $13.62M | $3.76B |
Volume | 132,438 | 836,200 |
Sector | Health | Technology |
52-Week High | $1.82 | $205.24 |
52-Week Low | $0.48 | $58.81 |
Typical Hold Time | 17 Days | 16 Days |
Enterprise Value | $3.79M | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Monday.com (MNDY) trades at $88.41, up 5.87% in the last session, showing strong momentum near 52-week highs. The stock maintains a bullish technical outlook with consistent earnings beats and robust revenue growth. Recent Q2 2026 EPS of $1.48 exceeded expectations by 33%, while enterprise customer growth accelerated to 37% year-over-year. The company's Elevate '26 conference highlights AI integration efforts, positioning it for continued market share gains in the work management software sector.
With 65% analyst buy ratings and a $108.64 consensus price target, MNDY offers 23% upside potential. However, elevated valuation multiples (P/E 37.7, EV/EBITDA 53.5) and increasing competition from Meta's enterprise push present near-term risks. The stock's current RSI near 88 suggests overbought conditions, though fundamental growth drivers remain intact for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
